U.S. stock night trading volatility: Palatin Tech fell 7.78% in after-hours trading, with executive insider trading raising market concerns

U.S. Stock Night Market Movements Palatin Tech fell 7.78% in the night market. Based on recent news, On November 18, Palatin Tech's Chief Operating Officer Wills Stephen T submitted Form 4 to the U.S. Securities and Exchange Commission, disclosing changes in his shareholding. Wills Stephen T exercised 832 stock options on November 14 and returned 229 shares at a price of $6.96 per share to cover the cost of exercising the options and/or tax liabilities. This insider trading information raised market concerns about the confidence of the company's management, leading to a decline in stock price. There have been no other significant news recently. The market is sensitive to insider trading information, resulting in stock price fluctuations. Stocks with High Trading Volume in the Industry Olema Pharmaceuticals fell 6.45% in the night market. Based on recent key news: On November 18, Olema Pharmaceuticals announced plans for a public offering of common stock and pre-funded warrants. This news caused the stock price to drop about 6% in after-hours trading. Source: Reuters On November 18, Roche's oral drug giredestrant showed positive results in late-stage trials, reducing the risk of postoperative recurrence of breast cancer, which drove Olema's stock price up 136.4% that day. Source: Reuters On November 18, Olema terminated its ATM common stock prospectus dated January 6, further affecting market confidence in its stock. Source: Reuters The biotechnology industry is highly volatile, and investment should be approached with caution. Kazia rose 51.04% in the night market. Based on recent news: On November 18, Kazia Therapeutics announced progress in its project targeting PD-L1 protein resistant forms and plans to apply for an FDA Type C meeting, as the paxalisib study showed strong overall survival signals. This news boosted market confidence, driving the stock price up. On November 18, the company disclosed that it received a notification from Nasdaq regarding its failure to meet minimum market capitalization requirements and must regain compliance by November 10. Despite facing compliance pressure, investor optimism regarding its R&D progress still dominated the market. On November 18, Kazia made progress in its glioblastoma project and plans to apply for an FDA meeting to further advance the research. This news further enhanced investor confidence in the company's future development. The biotechnology industry has been active recently, with significant capital inflows. Can-Fite BioPharma fell 6.24% in the night market. Based on recent news: On November 18, Can-Fite BioPharma announced that its main drug Namodenoson received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and was granted fast track designation by the FDA This news has attracted market attention, leading to a 51.27% increase in stock price during pre-market trading. On November 18, Can-Fite BioPharma released the latest progress of its clinical trials, showing significant efficacy of its drugs in treating hepatocellular carcinoma, metabolic dysfunction-associated fatty liver disease, and pancreatic cancer. This news boosted market confidence, but due to the previous significant rise in stock price, some investors chose to take profits, resulting in a price pullback. On November 19, D. Boral Capital maintained its target price for Can-Fite BioPharma at $11 per share. Although analysts are optimistic about the company's prospects, the market remains cautious about the volatility of the stock price in the short term. The biopharmaceutical industry has been quite volatile recently, and investors should exercise caution